Why the study?
Despite the conserved functional phenotype of the aged heart, a unifying mechanistic framework linking these functional features to their active molecular, genetic, and epigenetic drivers remains lacking.
Design
Integrative review
Answers are grounded in this paper and cite their sources.
Supports metabolic targets for cardiac aging research; leaves open clinical translation pending interventional trials.
Cardiac aging has long been viewed as the slow mechanical wearing of an engine; however, recent advances in single-cell transcriptomics, spatial metabolomics, and epigenomic profiling indicate that it is an active, genetically and epigenetically regulated biological program. Despite the conserved functional phenotype of the aged heart, reduced energetic reserve, diastolic stiffness, β-adrenergic desensitization, electrical instability, and regenerative failure, a unifying mechanistic framework that links these features to their molecular drivers remains lacking. In this review, we integrate functional, metabolic, transcriptomic, and epigenomic evidence to construct a top-down model of cardiac aging that traces functional decline through progressive metabolic rewiring, cell-type–specific transcriptional drift, and stochastic epigenetic remodeling. We position the FABP–PPARα/δ–NAD + –PGC-1α axis as the central integrative hub through which the metabolic state of the cardiomyocyte is translated into transcriptional output. Age-associated decline in this axis; driven by reduced FABP3-mediated ligand delivery, NAD + depletion, and sirtuin inactivation; progressively collapses fatty acid oxidation capacity and disrupts the metabolite cofactor signals (NAD + , acetyl-CoA, α-ketoglutarate) that maintain epigenetic fidelity. This metabolic–epigenetic uncoupling, in turn, erodes cell-type–specific identity and amplifies inflammaging across cardiomyocytes, fibroblasts, and the cardiac immune compartment. We propose that cardiac aging is governed by three interconnected, heart-specific hallmarks, metabolic inflexibility, transcriptional identity drift, and energetic–epigenetic uncoupling, that together refine the universal hallmarks of aging into a cardiac-specific model. Finally, we examine emerging biomarkers (cardiac methylation clocks, circulating FABPs, NAD + metabolome, GDF-15) and rejuvenation strategies (NAD + boosters, PPAR agonists, senolytics, partial reprogramming, exercise) that target this integrative network, highlighting the metabolic–epigenetic interface as the most actionable axis for therapeutic intervention against cardiac aging.
No takes yet. Share an insight, caveat, or question.
Salama et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: